Novel xanthine oxidase inhibitors as a therapeutic agent or a preventive agent for gout and hyperuricemia

被引：0
|
作者：
Kawana, Asahi [1 ]
Kanazawa, Chikashi [1 ]
Takahashi, Yoshimasa [1 ]
Muroga, Yumiko [1 ]
Imazeki, Mariko [1 ]
Nakada, Yoshio [1 ]
机构：
[1] Teijin Pharma Ltd, Hino, Tokyo, Japan
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2015年 / 250卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
139
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Discovery of novel xanthone derivatives as xanthine oxidase inhibitors
    Hu, Lina
    Hu, Honggang
    Wu, Weifeng
    Chai, Xiaoyun
    Luo, Jianfei
    Wu, Qiuye
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (13) : 4013 - 4015
  • [32] Triarylcarboxylic acid derivatives as novel xanthine oxidase inhibitors
    Miyata, Junji
    Kubota, Hirokazu
    Hattori, Kazuyuki
    Asano, Toru
    Watanabe, Junko
    Munakata, Ryosuke
    Kamikawa, Akio
    Kageyama, Michihito
    Naito, Ryo
    Kawakami, Masakatsu
    Takeuchi, Makoto
    Ohta, Mitsuaki
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [33] Recollections on the discovery of factor VIIa as a novel therapeutic agent for hemophiliacs with inhibitors
    Kisiel, W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (07) : 1053 - 1056
  • [34] Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout
    Hill-McManus, Daniel
    Marshall, Scott
    Soto, Elena
    Hughes, Dyfrig A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (03) : 652 - 660
  • [35] Physicochemical features and structural analysis of xanthine oxidase as a potential therapeutic target to prevent gout
    Nawaz, Muhammad Zohaib
    Ain, Qurat-ul
    Zahid, Sara
    Zulfiqar, Tooba
    Attique, Syed Awais
    Bilal, Muhammad
    Alghamdi, Huda Ahmed
    Yan, Wei
    Iqbal, Hafiz M. N.
    JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES, 2020, 13 (01) : 616 - 628
  • [36] Xanthine oxidase inhibitors may prevent or slow chronic kidney disease even in the absence of hyperuricemia
    Eleftheriadis, Theodoros
    Pissas, Georgios
    Liakopoulos, Vassilios
    Stefanidis, Ioannis
    KIDNEY INTERNATIONAL, 2018, 94 (04) : 830 - 831
  • [37] Synthesis and evaluation of hydroxychalcones as multifunctional non-purine xanthine oxidase inhibitors for the treatment of hyperuricemia
    Xie, Zhaodi
    Luo, Xiaoting
    Zou, Zhuan
    Zhang, Xiao
    Huang, Feifei
    Li, Ruishan
    Liao, Shijie
    Liu, Yun
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (15) : 3602 - 3606
  • [38] Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine Oxidase/Xanthine dehydrogenase inhibitor, for gout and hyperuricemia.
    Kamatani, N
    Fujimori, S
    Hada, T
    Hosoya, T
    Kato, R
    Matsuzawa, Y
    Ueda, T
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S530 - S530
  • [39] Pegloticase: A Novel Agent for Treatment-Refractory Gout
    Shannon, Jennifer A.
    Cole, Sabrina W.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (03) : 368 - 376
  • [40] PROTECTIVE AND PREVENTIVE THERAPEUTIC STRATEGIES - MONOAMINE-OXIDASE INHIBITORS
    TETRUD, JW
    LANGSTON, JW
    NEUROLOGIC CLINICS, 1992, 10 (02) : 541 - 552
12345